Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
Tranchand B, et al. Among authors: rebattu p.
Cancer Chemother Pharmacol. 1998;41(4):281-91. doi: 10.1007/s002800050741.
Cancer Chemother Pharmacol. 1998.
PMID: 9488597
Clinical Trial.